Primary CNS Lymphoma Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
Conditions: Primary Central Nervous System Lymphoma; Secondary Central Nervous System Lymphoma Intervention: Drug: GNC-038 Sponsors: Sichuan Baili Pharmaceutical Co., Ltd.; SystImmune Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 3, 2022 Category: Research Source Type: clinical trials
